Therapy Areas: Oncology
Genmab reports USD75m sales milestone in DARZALEX under collaboration with Janssen
9 January 2019 -

Genmab A/S (CPH:GEN), a biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer, announced on Tuesday the achievement of a USD75m sales volume milestone in its DARZALEX (daratumumab) collaboration with Janssen Biotech Inc (Janssen).

The company said this milestone was triggered by confirmation by Janssen that sales of DARZALEX reached USD2bn in the calendar year of 2018.

In August 2012, Genmab had granted Janssen an exclusive worldwide license to develop, manufacture and commercialise DARZALEX.

According to the company, this milestone payment was included in the financial guidance issued by it originally on 21 February 2018 and then reiterated in subsequent quarterly financial reports, most recently on 14 November 2018. Therefore, there is no change to the company's financial guidance for 2018.